Table 1 Clinical and laboratory evaluation, including treatment lines
Month/Year | Clinical course (diagnosis / progress / treatment) | Timepoint laboratory parameters: | IgM (g/L) | dFLC (mg/L) | Best achieved hematologic/organ response | NT-proBNP (ng/L) | Creatinine (mg/dL) | Proteinuria (g/day) |
|---|---|---|---|---|---|---|---|---|
Dec 2016 | initial AL diagnosis | At diagnosis (Dec 2016) | 12.3 | 79.5 | - | 1700 NYHA II | 1.07 | 5.177 |
Dec 2016 | treatment with R-Bendamustine | After treatment (May 2017) | 3.03 | 27.9 | VGPR | 2642 | 1.03 | 3.209 |
Nov 2018 | progress | At progress (Nov 2018) | 4.46 | 68.8 | - | 2295 | 1.20 | 0.802 |
Nov 2018 | mobilisation chemotherapy (cyclophosphamide/dexamethasone) with stem cell collection | After treatment (Dec 2018) | 3.47 | 66.6 | Renal response | 3129 | 1.11 | 0.324 |
Jan 2019 | consolidation—autologous stem cell transplantation conditioned with HD melphalan (200mg/m2) | After treatment (Apr 2019) | 1.31 | 11.1 | VGPR | 1859 | 1.24 | 0.273 |
Oct 2021 | progress | At progress (Oct 2021) | 6.36 | 149.6 | - | 2109 | 1.34 | 0.148 |
Apr 2022 | bridging with R-Bortezomib | After bridging (Jun 2022) | 4.74 | 127.1 | non-response | 1522 | 1.30 | 0.168 |
Aug 2022 | prior admission for CAR T cell infusion | Prior CAR T cell infusion (Aug 2022) | 3.33 | 105.4 | - | 1916 | 1.20 | 0.156 |
Aug 2022 | lymphodepleting chemotherapy (cyclophosphamide 500mg/m2/day and fludarabine 30mg/m2/day on days -4, -3 and -2) and CAR T cell infusion | After CAR T cell infusion (Sept 2022) | 1.83 | 83.6 | non-response | 1868 | 1.84 | - |
Nov 2022 | 3-month CAR T cell follow-up | 3-month follow-up (Nov 2022) | 0.99 | 54.6 | PR | 2047 | 1.43 | - |
Feb 2023 | 6-month CAR T cell follow-up | 6-month follow-up (Feb 2023) | 0.91 | 30.2 | VGPR | 2544 | 1.23 | 0.171 |